ClinicalTrials.gg
Not yet recruitingNCT07707089Updated Jul 16, 2026

Evaluation of AI-Mouse Use in Patients With Hand and Wrist Conditions

An interventional study of AI-Assisted Computer Input System and Conventional Computer Mouse in Carpal Tunnel Syndrome (CTS), Wounds and Injuries, Hands and Wounds and Injuries, Wrists, sponsored by Nazarbayev University. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-16.

Sponsored by Nazarbayev University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

People with hand and wrist conditions, such as carpal tunnel syndrome or hand injuries, often experience pain and discomfort when using a computer mouse. This study will evaluate a new artificial intelligence (AI)-assisted computer input system ("AI-mouse") designed to reduce the amount of hand movement needed during computer tasks. Participants will complete short computer-based tasks using both a conventional mouse and the AI-assisted system while researchers measure task performance, muscle activity using surface electromyography (EMG), and participants' ratings of pain, physical strain, and usability. The study aims to determine whether the AI-assisted system can reduce physical effort and muscle load while maintaining effective computer interaction. Findings may help improve accessible computer technologies and support the development of ergonomic tools for people with hand and wrist impairments.

02

Conditions studied

  • Carpal Tunnel Syndrome (CTS)
  • Wounds and Injuries, Hands
  • Wounds and Injuries, Wrists
  • Hand Injuries
  • Wrist Injuries
03

In context

Carpal Tunnel Syndrome

587 studies on the registry are indexed under Carpal Tunnel Syndrome; 134 are open to participants now.

This study's planned enrollment of 15 is below the median of 60 across 443 interventional studies indexed under Carpal Tunnel Syndrome.

Browse Carpal Tunnel Syndrome studies →

Lead sponsor

Nazarbayev University is the lead sponsor of 15 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-65 years
  • Diagnosis of a hand or wrist condition, including carpal tunnel syndrome or hand/wrist injury.
  • Receiving care at the Hand Surgery Department of the National Scientific Center of Traumatology and Orthopedics.
  • Medically stable and assessed by a study physician as able to safely perform light computer-based hand movements.
  • Able to understand the study procedures and provide written .
  • Normal or corrected-to-normal vision sufficient to complete computer-based tasks.

Exclusion criteria

Exclusion Criteria:

  • Severe pain or acute symptoms that may be aggravated by computer task performance.
  • Postoperative restrictions limiting hand or wrist movement.
  • Severe motor impairment preventing completion of the study tasks.
  • Cognitive or neurological disorders that interfere with understanding study procedures or task performance.
  • Uncorrected visual impairment that interferes with computer use.
  • Any medical condition that, in the opinion of the study physician, would make participation unsafe.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Active comparator
    Conventional Mouse

    Participants perform standardized computer pointing tasks using a conventional computer mouse. Performance (task completion time, error rate, throughput), surface electromyography (EMG) of upper-limb muscles, and participant-reported outcomes (pain, physical strain, and usability) are assessed during task completion.

    Device: Conventional Computer Mouse

  • Experimental
    AI-Mouse (Preview-Accept-Discard [PAD] System)

    Participants perform the same standardized computer tasks using the AI-Mouse, a predictive human-computer interaction system based on the Preview-Accept-Discard (PAD) paradigm. The system generates AI-assisted action suggestions that can be accepted or discarded using minimal keyboard input, reducing cursor movement. Performance, surface electromyography (EMG), and participant-reported outcomes (pain, physical strain, and usability) are assessed during task completion.

    Device: AI-Assisted Computer Input System

Interventions

  • DeviceAI-Assisted Computer Input System

    A non-invasive computer input system that uses artificial intelligence to predict the user's intended on-screen action. Instead of relying primarily on continuous cursor movement and mouse clicking, the system presents predicted actions that participants can preview, accept, or discard using minimal keyboard input. The intervention is designed to reduce repetitive hand movements during computer interaction while preserving user control. Participants complete standardized computer tasks using the system during a single study session lasting less than four minutes.

  • DeviceConventional Computer Mouse

    A standard computer mouse used for conventional point-and-click interaction. Participants complete the same standardized computer tasks as in the experimental condition, allowing direct comparison of task performance, upper-limb muscle activity measured by surface electromyography (EMG), and participant-reported pain, physical strain, and usability.

06

What researchers measure

Primary outcomes

  1. APDF90 surface electromyography (sEMG) amplitude

    90th percentile amplitude probability distribution function (APDF90) of the processed sEMG envelope recorded from selected upper-limb muscles during standardized computer tasks.

    Time frame: Baseline (during each intervention condition on Day 1)

  2. Muscular rest time

    Percentage of task duration during which the processed sEMG envelope remained below the predefined muscular-rest threshold of 2 µV.

    Time frame: Baseline (during each intervention condition on Day 1)

Secondary outcomes

  1. Integrated squared dynamic acceleration

    Cumulative dynamic movement workload measured by tri-axial accelerometry and expressed as integrated squared dynamic acceleration (mG²·s).

    Time frame: Baseline (during each intervention condition on Day 1)

  2. 90th percentile dynamic acceleration

    Peak dynamic movement intensity measured by tri-axial accelerometry and expressed as the 90th percentile of dynamic acceleration (mG).

    Time frame: Baseline (during each intervention condition on Day 1)

  3. Task completion time

    Time required to complete the standardized computer task using the conventional mouse and the AI-assisted computer input system.

    Time frame: Baseline (during each intervention condition on Day 1)

  4. Error rate

    Percentage of incorrect target selections during the standardized computer task

    Time frame: Baseline (during each intervention condition on Day 1)

  5. Self-reported pain

    Participant-reported hand and wrist pain after completing each intervention condition, assessed using a numeric rating scale

    Time frame: Immediately after each intervention condition on Day 1

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Sep 2026, 2 months later.

Of 251 non-industry interventional studies with no phase under Carpal Tunnel Syndrome, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 27. This study's planned 2 months is below that.

Counting every sponsor, half of 261 studies reached it within 12 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 16, 2026
StartEst.
Jul 2026
Primary completionEst.
Sep 2026
CompletionEst.
Oct 2026
Last update
Jul 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07707089
Lead sponsor
Nazarbayev University
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jul 2026 (estimated)
Primary completion
Sep 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jul 16, 2026

Study contacts

Jose Berengueres, PhD
Contact
jose.berengueres@nu.edu.kz
+7 778 358 18 26
Dina Kalinina, MD
Contact
dina.kalinina@nu.edu.kz
+77756238719

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion